U.S. Government Funded Research Brings Shorter Tuberculosis Treatment Regimens to New York City
Statement / Press • 2022We applaud the New York City Department of Health and Mental Hygiene (DoHMH) for its leadership as one of the first TB programs in the U.S. and globally to introduce a new four-month regimen for the treatment of drug-susceptible tuberculosis (TB).
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
Statement / Press • 2021The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.
Community Movements Across Africa, Asia and South America Celebrate Roll-Out of Short-Course, Patient-Friendly TB Preventive Therapy
Statement / Press • 2021Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.
Delivering on the Promise of Long-Acting Technologies
TAGline • 2021By Susan Swindells* and Mark Harrington This issue of TAGline explores the exciting opportunities and challenges that come with the development of long-acting formulations for the prevention and treatment of infectious diseases. For many years to date, patients and providers have welcomed long-acting medications for other conditions such as schizophrenia, osteoporosis, and contraception. These delivery…
Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing
Statement / Press • 2021TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.
Statement from TAG’s TB Project on Today’s WHO Global TB Report
Statement / Press • 2021Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.
Injectables Redux: Developing Acceptable Long-Acting Formulations for TB Prevention Amidst a Push for All-Oral Treatment
TAGline • 2021By David Branigan Ensuring access to tuberculosis (TB) preventive treatment for people most at risk of developing active TB is one of the key interventions required to end TB.1 Central to these efforts is the push to scale up short course, rifapentine-based TB preventive treatment (TPT) in countries with high burdens of TB — similar…
Know Your CAB: Community Experts Shaping the Long-Acting Technologies Pipeline
TAGline • 2021By Bryn Gay, Joelle Dountio Ofimboudem, and Kenly Sikwese* Meaningful and equitable community engagement is essential to ensuring that long-acting technologies (LATs) clinical research is conducted in ways that are safe, ethical, appropriate, and responsive to community priorities and needs.1 To advance the community engagement work, Treatment Action Group (TAG) and the African Community Advisory…
Launch of Public Health Partnership to Tackle the Silent Epidemic of Hepatitis C in Low- and Middle-Income Countries
Statement / Press • 2021The Drugs for Neglected Diseases initiative (DNDi), Médecins Sans Frontières (MSF), FIND, the global alliance for diagnostics, and the Treatment Action Group are joining forces to tackle a ‘silent’ public health injustice: the continuing disparities in access to diagnostics and treatment for the hepatitis C virus (HCV) in low- and middle-income countries (LMICs), home to 75% of those living with this viral illness.
Landmark TB Trials Results Published in New England Journal of Medicine
Statement / Press • 2021Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.